Outcomes
| Study author, year | Follow-up duration, months | Enucleation rate | Globe salvage, % by group | Ocular survival rate, % | Rate of metastatic disease, % | Recurrence rate, % |
| Peterson et al
12
2011 | 8.6 (3–12) | 24 | 65 | 77 | ||
| Suzuki et al
13
2011 | 79 (58) | A (100) B (88) C (65) D (45) E (30) | 2.3 | |||
| Marr et al
14
2012 | 14 (1–43) | 12 | 75 | 0 | ||
| Muen et al
15
2012 | 9 (3–16) | 13 | 80 | |||
| Thampi et al
16
2013 | 15 (1–29) | 30 | A–C (86) D–E (38) | 0 | ||
| Ghassemi et al
17
2014 | 17 (3–36) | 33 | 63 | 84 | 50 | |
| Shields et al
2
2014 | 19, mean | B–D (100) E (36) | 0 | |||
| Parareda et al
18
2014 | 29.5 (6–57) | 41.7 | 58 | |||
| Ong et al
20
2015 | 22 (5–43) | 41 | B–C (75) D–E (54) | |||
| Chen et al
4
2016 | 28 (9–65) | 7.7 | B (100) D (89) E (100) | 0 | ||
| Leal Leal et al
21
2016 | 14.3 (1.8–28) | 27 | 55 | |||
| Michaels et al
11
2016 | 36 | 58 | ||||
| Tuncer et al
22
2016 | 29 (6–55) | 33 | 67 | |||
| Chen et al
10
2017 | 9.1 (1–26) | 21.5 | B (100) C (100) D (79) E (62) | |||
| Munier et al
9
2017 | 0 | |||||
| Rishi et al
23
2017 | 80 | |||||
| Francis et al
8
2018 | 26.5 (0–119.7) | 96 | ||||
| Funes et al
25
2018 | 48.7 (12–79) | 32 | 63 | |||
| Hua et al
26
2018 | 14.2 (3–28) | 70.2 | 30 | 40 | 0 | |
| Kiratli et al
7
2018 | 4.0 (1–16) | 23.3 |